The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 24, 2018

Filed:

Dec. 10, 2014
Applicant:

Dow Global Technologies Llc, Midland, MI (US);

Inventors:

Paresh C. Sanghani, Carmel, IN (US);

Brandon A. Rodriguez, Houston, TX (US);

Christopher C. Stowers, Carmel, IN (US);

Amudhan Venkateswaran, Zionsville, IN (US);

Assignee:

Dow Global Technologies LLC, Midland, MI (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12P 7/64 (2006.01); C12P 7/24 (2006.01); C12P 7/26 (2006.01); C12P 7/40 (2006.01); C12N 9/04 (2006.01); C12N 1/20 (2006.01); C12N 1/14 (2006.01); C12N 9/10 (2006.01); C12N 9/88 (2006.01); C12N 15/52 (2006.01);
U.S. Cl.
CPC ...
C12P 7/6409 (2013.01); C12N 1/14 (2013.01); C12N 1/20 (2013.01); C12N 9/0006 (2013.01); C12N 9/1025 (2013.01); C12N 9/88 (2013.01); C12N 15/52 (2013.01); C12P 7/24 (2013.01); C12P 7/26 (2013.01); C12P 7/40 (2013.01); C12Y 101/01085 (2013.01); C12Y 203/03013 (2013.01); C12Y 402/01033 (2013.01);
Abstract

Modification of metabolic pathways includes genetically engineering at least one enzyme involved in elongating 2-ketoacids during leucine biosynthesis, and preferably at least isopropylmalate dehydrogenase or synthase (LeuB or LeuA in), to include at least such non-native enzyme, enzyme complex, or combination thereof to convert 2-ketobutyrate or 2-ketoisovalerate to a C7-C11 2-ketoacid, wherein the production of such is at a higher efficiency than if a purely native pathway is followed. The C7-C11 2-ketoacid may then be converted, via a native or genetically engineered thiamin dependent decarboxylase, to form a C6-C10 aldehyde having one less carbon than the C7-C11 2-ketoacid being converted. In some embodiments the C6-C10 aldehyde may then be converted via additional native or genetically engineered enzymes to form other C6-C10 products, including alcohols, carboxylic acids, and alkanes. This genetic engineering offers the opportunity for commercial scale of in vivo biosynthetic processes that may be more cost-efficient than non-biobased approaches to produce the same products.


Find Patent Forward Citations

Loading…